Exhibit 10.29

 

EMPLOYMENT AGREEMENT

 

AGREEMENT, dated as of December 13, 2001, between Transkaryotic Therapies, Inc.,
a Delaware corporation (the “Company”), and David Pendergast (the “Executive”).

 

1.             EMPLOYMENT.  The Company hereby employs the Executive and the
Executive hereby accepts employment, effective January 2, 2002 (the
“Commencement Date”), with the Company upon the terms and conditions herein set
forth.

 

2.             DUTIES.  The Executive shall be engaged as a full-time employee
to act as the Company’s Senior Vice President, Quality and Analytical
Development, and shall report to the Company’s Founder and Chief Executive
Officer.  The Executive shall perform the duties consistent with such position
as the Founder and Chief Executive Officer shall from time to time reasonably
designate, including formulation, bioassay development and analytical
development.  The Executive shall devote his entire time, attention and energies
to the business of the Company and shall not engage in any other business
activity or activities, whether or not such business activity is pursued for
gain, profit or other pecuniary advantage that, in the judgment of the Company,
may conflict with the proper performance of the Executive’s duties under this
Agreement.  Notwithstanding the foregoing, (a) with respect to businesses which
do not compete with the Company, the Executive may invest his personal or family
assets in such form or manner as will not require any services on the part of
the Executive in the operation of the affairs of the companies in which such
investments are made and in which his participation is solely that of an
investor, and (b) the Executive may purchase securities in any corporation whose
securities are regularly traded in recognized securities markets, provided that
such investments shall not result in his collectively owning beneficially at any
time one percent (1%) or more of the equity securities of any corporation
engaged in a business competitive to that of the Company.

 

3.             COMPENSATION.

 

(a)           Base Salary.  For services rendered under this Agreement, the
Company shall pay the Executive an annual salary of $280,000 (the “Base
Salary”), payable (after deduction of applicable withholding for Federal and
state income and payroll taxes) in equal semi-monthly installments.  The Company
may review the Executive’s compensation annually and make such increases to the
Base Salary as the Company determines are merited, based upon the Executive’s
performance and consistent with the Company’s compensation policies as
established by the Compensation Committee of the Company’s Board of Directors. 
Any such increase in annual Base Salary shall be communicated to the Executive
shortly after the January meeting of the Board of Directors and shall be made
effective on the first day of January each year.

 

(b)           Bonus. The Chief Executive Officer and the Executive shall
establish objective performance goals for the Executive for such calendar year. 
Upon the attainment of such performance goals, but subject to the overall
performance of the Company during such year, the Executive may be entitled to a
bonus targeted at twenty percent (20%) of base compensation, as determined by
the Compensation Committee of the Company’s Board of Directors.  Within thirty
(30) days after the close of each such calendar year, the Company shall evaluate
the attainment of the performance goals for such calendar year and determine the
amount of any performance bonus payable hereunder.  Any such performance bonus
shall be payable within ninety (90) days after the calendar year to which it
relates.

 

--------------------------------------------------------------------------------

 

 

 

(c)           Fringe Benefits.  In addition to Base Salary and Bonus payments
under Sections 3(a), (b), and (c) above, the Executive shall be eligible for and
participate in such fringe benefits, in accordance with the terms of each such
benefit, as shall be generally provided to executives of the company, including
incentive compensation, the Company’s 401(k) Plan, health and dental insurance,
and any retirement programs, stock options plans or employee stock purchase
plans which may be adopted from time to time during the term hereof by the
Company.  Nothing herein contained shall be deemed to preclude the Company from
granting such additional compensation or benefits to the Executive as it shall
in its sole discretion determine.

 

(d)           Stock Options.  Upon authorization by the Company’s Board of
Directors or Compensation Committee, the Company will promptly grant the
Executive under the Company’s 1993 Long-Term Incentive Plan (the “Plan”) a
nonstatutory stock option to purchase an aggregate of one hundred thousand
(100,000) shares of the Common Stock of the Company, par value $.01 per share,
at a purchase price equal to the bid price of the stock as of the close of
business on the last trading day before the Commencement Date.  Of such options,
8,334 will vest immediately upon your hire date, with the remaining 91,666
vesting annually for a period of six (6) years on the anniversary date of this
Agreement.  Such options shall be exercisable during the ten (10) year period
following its date of vesting and shall be subject to all the terms and
conditions of the Plan and the Company’s standard form of Stock Option
Agreement, copies of which have been delivered to the Executive separately.

 

4.             VACATION.  During the term of this Agreement, the Executive shall
be entitled to fifteen (15) annual vacation days accrued at the rate of 1.25
days per month.

 

5.             SICK LEAVE.  During the term of this Agreement, the Executive
shall be entitled to sick leave consistent with the Company’s customary sick
leave policy.

 

6.             EXPENSES.  During the term of this Agreement, the Company shall
reimburse the Executive in accordance with the Company’s customary policies for
all reasonable out-of-pocket expenses incurred by the Executive in connection
with the business of the Company and in performance of his duties under this
Agreement upon the Executive’s presentation to the Company of an itemized
accounting of such expenses with reasonable supporting data.

 

7.             TERM.

 

(a)           The Executive’s employment under this Agreement shall commence on
the Commencement Date and shall continue until terminated by the Company as
provided in this Section 7(a) or by the Executive as provided in Section 7(c)
below.  The Company may, at its election, terminate the obligations of the
Company under this Agreement as follows:

 

(i)            Upon at least sixty (60) days’ prior written notice if the
Executive becomes physically or mentally incapacitated or is injured so that he
is unable to perform the services required of him hereunder and such inability
to perform continues for a period in excess of six (6) months and is continuing
at the time of such notice; or

 

2

--------------------------------------------------------------------------------

 

 

(ii)           For “Cause” upon prior written notice of such termination to the
Executive.  For purposes of this Agreement, the Company shall have “Cause” to
terminate its obligations hereunder upon (a) the Company’s determination that
the Executive has ceased or failed to substantially perform his duties hereunder
(other than as a result of his incapacity due to physical or mental illness or
injury), and at least thirty (30) days’ prior written notice to the Executive,
(b) the Executive’s death, (c) the Company’s determination that the Executive
has engaged or is about to engage in conduct materially injurious to the
Company, (d) the Executive’s having been convicted of a felony, or (e) the
Executive’s participation in activities proscribed by the provisions of Sections
2, 9, or 11 hereof or material breach of any of the other covenants herein; or

 

(iii)          Without Cause upon at least sixty (60) days’ prior written notice
of such termination to the Executive.

 

(b)           If, subsequent to six (6) months of the date the Executive’s
employment hereunder commences, this Agreement is terminated pursuant to Section
7(a)(i) above, subject to Section 11(d) below, the Executive shall receive
severance pay until the fourth anniversary of the date hereof at the rate of one
hundred percent (100%) of Base Salary, reduced by applicable payroll taxes and
further reduced by the amount received by the Executive during such period under
any Company maintained disability insurance policy or plan or under Social
Security or similar laws.  Such severance payments shall be paid periodically to
the Executive as provided in Section 3(a) for the payment of Base Salary.  If
this Agreement is terminated at any time pursuant to Section 7(a)(ii) above, the
Executive shall receive no severance pay.  If this Agreement is terminated
pursuant to Section 7(a)(iii) above after one year of service or more, the
Executive shall receive severance pay, for a period of twelve (12) months from
and after such termination, equal to the Base Salary less the amount, if any,
earned by the Executive during such twelve (12) month period, whether as salary,
consulting fees, deferred payments or other direct or indirect compensation. 
Such severance payments (less applicable withholding and payroll taxes) shall be
paid periodically to the Executive as provided in Section 3(a) for the payment
of Base Salary.

 

(c)           The Executive may terminate his employment under this Agreement
upon breach by the Company or for Good Reason.  Termination of the Executive’s
employment for “breach” shall mean that the Company fails to perform, in any
material respect, its obligations under the Agreement, after written notice to
the Company setting forth in reasonable detail the nature of such breach, if
such breach remains uncured for a period of 90 days following such notice to the
Company.  Termination of the Executive’s employment for “Good Reason” shall only
mean termination based on (i) a substantial diminution in the responsibilities,
duties, and powers of the Executive including, without limitation, the Executive
ceasing to be the Senior Vice President, Quality and Analytical Development of
the Company; and/or (ii) the relocation of the Executive’s present office
location to an area more than 100 miles from the metropolitan Boston area.  In
the event of termination of employment pursuant to this paragraph (c), the
Company shall pay to the Executive severance pay for a period of twelve (12)
months in an amount equal to (x) 100% of the Executive’s Base Salary immediately
prior to such termination; plus, (y) any bonus payment for the fiscal year
preceding the year in which such termination occurs that was earned but not paid
at the date of such termination.  The Executive shall not be required to
mitigate the amount of any payment provided for in this paragraph (c) by seeking
other employment or otherwise, but the amount of any payment or benefit provided
for in this paragraph (c) shall be reduced by an amount equal to any
compensation earned by the Executive as a result of employment with another
employer after termination of employment with the Company, or otherwise.

 

3

--------------------------------------------------------------------------------

 

 

 

(d)           The Executive may terminate his employment under this Agreement
for any reason upon at least sixty (60) days’ prior written notice.  In the
event of any such termination of employment pursuant to this paragraph (d)
(excluding any termination of employment paragraph (c) above), the Executive
shall not be entitled to any severance payments.

 

8.             REPRESENTATIONS.  The Executive hereby represents to the Company
that (a) he is legally entitled to enter into this Agreement and to perform the
services and other obligations contemplated herein; (b) he has, and throughout
the term of this Agreement will continue to have, the full right, power and
authority, subject to no rights of third parties, to grant to the Company the
rights contemplated by Section 10 hereof; and (c) he is not subject to any
agreement, rule, regulation or policy of any university, research institution or
other third party inconsistent with the foregoing representations.

 

9.             DISCLOSURE OF INFORMATION.

 

(a)           The Executive recognizes and acknowledges that the Company’s trade
secrets, know-how and proprietary processes as they may exist from time to time
(including, without limitation, information regarding methods, cultures,
vectors, plasmids, synthesis techniques, nucleic acid sequences, purification
techniques, gene activation and gene therapy techniques, treatments for
lysosomal storage disorders, and assay procedures) as well as the Company’s
confidential business plans and financial data are valuable, special and unique
assets of the Company’s business, access to and knowledge of which are essential
to the performance of the Executive’s duties hereunder.  The Executive shall
not, during or after the term of his employment by the Company, in whole or in
part, disclose such secrets, know-how, processes, business plans or financial
data to any person, firm, corporation, association or other entity for any
reason or purpose whatsoever, nor shall the Executive make use of any such
property for his own purposes or for the benefit of any person, firm,
corporation or other entity (except the Company) under any circumstances during
or after the term of his employment, provided that after the term of his
employment, these restrictions shall not apply to such secrets, know-how, and
processes which the Executive can establish by competent proof:

 

(i)            were known, other than under binder of secrecy, to the Executive
prior to his employment by the Company;

 

(ii)           were passed into the public domain prior to or after their
development by or for the Company, other than through acts or omissions
attributable to the Executive; or

 

4

--------------------------------------------------------------------------------

 

(iii)          were subsequently obtained, other than under binder of secrecy,
from a third party not acquiring the information under an obligation of
confidentiality from the disclosing party.

 

(b)           Upon termination of his employment hereunder, the Executive shall
promptly turn over to the Company all originals and copies which he may have of
any of the Company’s confidential information described in this Section 9.

 

10.           INTELLECTUAL PROPERTY.  The Executive hereby sells, transfers, and
assigns to the Company, or to any person or entity designated by the Company,
the entire right, title, and interest of the Executive in and to all inventions,
ideas, discoveries, and improvements (including, without limitation, all
microorganisms, strains or cultures) whether patented or unpatented, and
copyrightable material made or conceived by the Executive, solely or jointly,
during the term hereof, which arise out of research or other activities
conducted by, for or under the direction of the Company, whether or not
conducted at the Company’s facilities, or which relate to methods, apparatus,
designs, products, processes or devices, sold, leased, used or under
consideration or development by the Company.  The Executive acknowledges that
all copyrightable materials developed or produced by the Executive within the
scope of his employment constitute works made for hire.  The Executive shall
communicate promptly and disclose to the Company, in such form as the Company
may reasonably request, all information, details, and data pertaining to any
such inventions, ideas, discoveries, and improvements; and the Executive shall
execute and deliver to the Company such formal transfers and assignments and
such other papers and documents and shall give such testimony as may be
necessary or required of the Executive to permit the Company or any person or
entity designated by the Company to file and prosecute patent applications and,
as to copyrightable material, to obtain copyrights thereof.  Any such invention,
idea, discovery or improvement disclosed by the Executive within one (1) year
following the termination of this Agreement shall be deemed to fall within the
provisions of this Section 10 unless proved to have been first conceived and
made following such termination.

 

11.           COVENANTS NOT TO COMPETE OR INTERFERE.

 

(a)           Subject to Section 11(b) below, during the term of this Agreement
and the period ending twenty-four (24) months from and after the termination of
the Executive’s employment hereunder, the Executive shall not engage in any
business (whether as an officer, director, owner, employee, partner, consultant,
advisor or other direct or indirect participant) engaged in: (a) the development
of (1) non-viral gene therapy, (2) gene targeting, (3) gene activation methods,
or (4) treatments for lysosomal storage disorders; (b) the sale of products or
rendering of services related to (1) non-viral gene therapy, (2) gene targeting,
(3) gene activation methods, or (4) lysosomal storage disorders; or (c) any
other activity which directly competes with any of the Company’s business
activities.  This Agreement shall not be construed to restrict the Executive’s
right to be employed as a faculty member of any university or employee of any
nonprofit agency or foundation after any termination of this Agreement where
this covenant not to compete shall continue to be in effect.  During the period
in which this covenant not to compete is in effect, the Executive also shall not
interfere with, disrupt or attempt to disrupt the relationship, contractual or
otherwise, between the Company and any customer, supplier, lessor, lessee,
employee, consultant, research partner or investor of the Company.

 

5

--------------------------------------------------------------------------------

 

(b)           If this Agreement is terminated by the Company pursuant to Section
7(a)(iii) above, the provisions of the first sentence of Section 11(a) shall
apply until twelve (12) months from and after such termination.

 

(c)           It is the desire and intent of the parties that the provisions of
this Section 11 shall be enforced to the fullest extent permissible under the
laws and public policies applied in each jurisdiction in which enforcement is
sought.  Accordingly, if any particular Subsection or portion of this Section 11
shall be adjudicated to be invalid or unenforceable, this Section 11 shall be
deemed amended to delete therefrom the portion thus adjudicated to be invalid or
unenforceable, such deletion to apply only with respect to the operation of this
Section in the particular jurisdiction in which such adjudication is made.

 

(d)           In the event of any breach of the provisions of this Section 11 by
the Executive, any and all rights of the Executive to receive severance payments
under Section 7(b) above shall automatically terminate.

 

12.           INJUNCTIVE RELIEF.  If there is a breach or threatened breach of
the provisions of Section 9, 10, or 11 of this Agreement, the Company shall be
entitled to an injunction, without bond, restraining the Executive from such
breach.  Nothing herein shall be construed as prohibiting the Company from
pursuing any other remedies for such breach or threatened breach.

 

13.           INSURANCE.  The Company may, at its election and for its benefit,
insure the Executive against accidental loss or death, and the Executive shall
submit to such physical examinations and supply such information as may be
required in connection therewith.

 

14.           NOTICES.  Any notice required or permitted to be given under this
Agreement to the Executive shall be sufficient if in writing and if sent by
certified or registered mail to his residence, or in the case of the Company, to
Transkaryotic Therapies, Inc., 195 Albany Street, Cambridge, MA  02139,
Attention:  Chief Executive Officer, or to such other offices or addresses as
the company shall designate from time to time in writing to the Executive.  Any
such notice shall be effective on the earlier of (a) the date on which it is
personally delivered or (b) three (3) days after it is deposited in the United
States mails, postage prepaid.

 

15.           WAIVER OF BREACH.  A waiver by the Company or the Executive of a
breach of any provision of this Agreement by the other party shall not operate
or be construed as a waiver of any subsequent breach by the other party.

 

16.           GOVERNING LAW.  This Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the Commonwealth of
Massachusetts without giving effect to the conflicts of laws provisions thereof.

 

17.           ASSIGNMENT.  This Agreement may be assigned, without the consent
of the Executive, by the Company to any person, partnership, corporation or
other entity which succeeds to the business of the Company or which has
purchased substantially all the assets of the Company, provided such assignee
assumes all the liabilities of the Company hereunder.

 

6

--------------------------------------------------------------------------------

 

18.           ENTIRE AGREEMENT.  This Agreement contains the entire agreement of
the parties and supersedes any prior understandings or agreements between the
Executive and the Company.  This agreement may be changed only by an agreement
in writing signed by the party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 

IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of
the date first above written.

 

 

TRANSKARYOTIC THERAPIES, INC.

 

 

 

 

 

 

 

By:

/s/ Richard F Selden

 

 

 

Richard F Selden, M.D., Ph.D.

 

 

Founder and Chief Executive Officer

 

 

 

 

 

 

 

 

/s/ David Pendergast

 

 

 

David Pendergast

 

7

--------------------------------------------------------------------------------